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Simple Summary: Malignant pleural mesothelioma (MPM) is a cancer affecting the covering of
the lung (the pleura). This commonly causes a build-up of fluid around the lung, called a pleural
effusion. Draining the pleural effusion can improve breathlessness and tests can be performed on the
fluid. However, for most patients with MPM, a sample of tissue from the pleura, called a biopsy, is
required in addition to make the diagnosis. Sometimes, due to medical conditions, frailty or personal
preference, patients may not be able to have a biopsy. This review article discusses additional tests
used in this situation to help doctors make a diagnosis of MPM. These techniques include tests on
pleural fluid using “immunocytochemistry” methods, biomarkers and scans. Although, without a
biopsy, no test in isolation can diagnose MPM, combining information from different types of tests
and reviewing results among a specialist team can enable a consensus diagnosis.
Abstract: For a number of patients presenting with an undiagnosed pleural effusion, frailty, medical
co-morbidity or personal choice may preclude the use of pleural biopsy, the gold standard investi-
gation for diagnosis of malignant pleural mesothelioma (MPM). In this review article, we outline
the most recent evidence on ancillary diagnostic tests which may be used to support a diagnosis
of MPM where histological samples cannot be obtained or where results are non-diagnostic. Im-
munocytochemical markers, molecular techniques, diagnostic biomarkers and imaging techniques
are discussed. No adjunctive test has a sensitivity and specificity profile to support use in isolation;
however, correlation of pleural fluid cytology with relevant radiology and supplementary biomarkers
can enable an MDT-consensus clinico-radiological-cytological diagnosis to be made where further
invasive tests are not possible or not appropriate. Diagnostic challenges surrounding non-epithelioid
MPM are recognised, and there is a critical need for reliable and non-invasive investigative tools in
this population.
Keywords: malignant pleural mesothelioma; pleural effusion; biomarkers
1. Introduction
Arising predominantly from the pleural or peritoneal surface (less commonly the
pericardium and tunica vaginalis), mesothelioma grows insidiously, often resulting in an
advanced stage at clinical presentation. Whilst research into innovative treatment options is
an active area of interest and brings new hope for patients, malignant pleural mesothelioma
(MPM) remains relatively refractory to conventional therapies. Consequently, prognosis is
poor, with a median survival of just 9.5 months and a 3-year survival rate of 12% [1,2].
An association with asbestos was first observed in 1960 in a case series of 33 patients
with pleural mesothelioma from the Asbestos Hills in the Cape Province of South Africa [3].
Today, 85% of all mesotheliomas in males are attributable to occupational asbestos exposure,
with para-occupational exposure being a recognised cause in women [4]. Despite a ban
on asbestos products in 52 countries by 2010 [5], the long latency period from exposure
to disease (typically 30–40 years) and continued unregulated use in countries such as
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India, Brazil and Russia means that MPM continues to represent a significant global health
concern, with an estimated burden of 38,400 cases per year worldwide [6].
Other aetiological mechanisms include genetic predisposition, with inherited germline
mutations of the BRCA 1-associated protein (BAP1) gene (a tumour suppressor gene
involved in modulation of transcription and DNA repair) identified amongst families
with high incidence of mesothelioma in 2011 [7]. Exposure to other elongated mineral
particles (including environmental exposure to erionite and fluoro-edenite in Turkey, USA
and Mexico) and ionising radiation are also implicated [8]. Pathogenic mechanisms of
carcinogenesis following asbestos fibre inhalation highlight a cycle of genetic and cellular
damage with chronic inflammation [2,4,9–11].
Four main histological subtypes of MPM are described; epithelioid, sarcomatoid,
biphasic and desmoplastic, with epithelioid associated with the most favourable prognosis
(median survival of 13 months) and sarcomatoid the least (median survival 4 months) [12].
With no established role for surgical resection outside of clinical trials [1], histological
diagnosis of MPM typically relies on biopsy samples. Thoracoscopic pleural biopsy is
recommended as the gold standard for investigating an undiagnosed pleural effusion where
the differential includes MPM, with diagnostic yields of 95% and higher [13]. Alternatively,
where contrast-enhanced thoracic computed tomography (CT) demonstrates focal areas of
abnormal pleura, image-guided needle biopsy may be employed to obtain tissue [8,14,15].
There is a cohort of patients for whom frailty, medical co-morbidity or personal
choice preclude the use of invasive pleural biopsy. The 2020 UK National Mesothelioma
Report showed the median age of patients diagnosed with pleural mesothelioma was
76 years and that over 20% of patients had stage IV disease at diagnosis [16]. Furthermore,
a multinational population-based evaluation of 9014 patients demonstrated that more
than half of those diagnosed with mesothelioma were aged 70 years or older [17]. Given
demographic trends, the proportion of elderly patients will continue to rise over coming
decades, with increasing comorbidity further complicated by advanced stage at disease
presentation. Diagnostic approaches that are tolerable to and appropriate for patients
of higher age or with significant comorbidity are increasingly necessary. Additionally, a
proportion of patients who are considered suitable to undergo pleural biopsy at initial
assessment go on to have a protracted diagnostic pathway, with repeated procedures
yielding equivocal or non-diagnostic results.
Although international guidelines do not advocate cytology-based diagnoses of MPM
in patients who are fit for further diagnostic tests [1], the importance of obtaining a diagno-
sis for frail patients who are unable to undergo invasive procedures to obtain a biopsy is no
less significant. Confirmation of a diagnosis is important for future planning and to enable
patients to access financial compensation. In some regions, a multi-disciplinary team (MDT)
diagnosis based on cytological, radiological and clinical information is sufficient to avoid
requirements for a post-mortem examination after death [18].
In this article, we will explore and outline the most up-to-date evidence on ancillary
diagnostic tests currently available in clinical practice. We will focus on techniques which
may be used to support a diagnosis of MPM from cytological specimens and other less
invasive modalities, where histological samples cannot be obtained or where results may
be non-diagnostic.
2. Pleural Fluid (PF) Cytology
Diagnostic thoracentesis is the primary means of obtaining PF for evaluation and is
an essential step in the initial investigation of a unilateral pleural effusion [19]. Diagnostic
cytology on PF can spare the patient more invasive investigations to obtain a tissue biopsy,
reducing the risk of procedural complication with both cost and time saving in addition.
However, the diagnostic yield of MPM from conventional PF cytology alone is highly
variable, with sensitivity ranging from 16% to 73% [1]. In one study of 921 patients with an
undiagnosed unilateral pleural effusion, fluid cytology was diagnostic in only 9 of 148 (6%)
participants with MPM [20].
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Several factors contribute to the wide range of sensitivities quoted. Whilst epithelioid
cancers can shed malignant cells into pleural effusion fluid, this is rare in sarcomatoid sub-
types. Cytological diagnosis is usually limited, therefore, to the epithelioid subtype. Heavy
bloodstaining or rich inflammatory cell infiltrate may additionally reduce cellular yield in
effusion specimens. Concentration techniques such as cell block and cytospin preparations
can overcome these problems and enhance detection of malignant cells. Cell blocks can
also provide a substrate on which adjunctive tests, including immunocytochemical and
molecular techniques, can be applied. [8,21,22]
Cytologist experience is another important consideration, with cytopathology being
a recognised subspecialty in its own right. For example, morphological appearances of
benign reactive mesothelial cells can overlap with malignant cells, complicating diagnosis
and demanding meticulous assessment. The volume of PF submitted for analysis may
be an additional limitation [1,23], with the British Thoracic Society recommending that
20–40 mL should be sent for evaluation [19].
An important limitation on cytology-based diagnosis is the inability to determine
tumour invasion into the lung or chest wall on the basis of PF cytology alone [21,24].
Cytological yield in epithelioid mesothelioma is, however, higher in the presence of visceral
pleural invasion. In one study of 75 patients with epithelioid MPM, 37/45 (82%) with
positive PF cytology at initial thoracentesis had evidence of visceral pleural invasion at local
anaesthetic thoracoscopy (defined as masses, nodules, thickening or mixed appearance)
compared with 9/30 (30%) patients having negative cytology, giving an odds ratio for
an association between visceral pleural invasion and cytological positivity of 11.87 (95%
confidence interval (CI): not stated; p < 0.001) [25].
3. PF Immunohistochemistry (IHC) and Molecular Techniques
Initial cytomorphology may be sufficient to confirm the presence of malignant cells
in PF after routine staining and, in some cases, may confirm MPM. However, more of-
ten, ancillary techniques are required to discriminate benign from malignant mesothelial
populations and to differentiate MPM from carcinoma or neoplasms of other origins (for
example, melanoma). Recent advances in immunocytochemical and molecular testing have
facilitated these diagnostic steps [22,26].
3.1. Discriminating Benign from Malignant Mesothelial Populations
Reactive mesothelial proliferation is a common mimic of MPM (and metastatic car-
cinoma) and has numerous causes, including infection, pulmonary infarction, trauma,
autoimmune disease and drug reactions [27]. Cytomorphological features overlap with
MPM and include high cellularity, numerous mitotic figures and cytologic atypia. The
inability to evaluate tissue invasion in cytology-based specimens means that reactive
mesothelial proliferation is more frequently documented in cytologic specimens than in
tissue biopsies [24].
Certain immunocytochemical stains are more likely to be positive in benign mesothe-
lial cell proliferation and other stains in malignant mesothelial proliferation. However,
most IHC staining patterns do not reliably differentiate malignant from benign mesothe-
lial proliferation. Desmin, reported previously to favour benign reactive mesothelium,
shows positivity in up to 56% of mesotheliomas [28]. Similarly, whilst epithelial membrane
antigen (EMA), p53 and insulin-like growth-factor 2 messenger ribonucleic acid (RNA)-
binding protein 3 (IMP-3) may support a diagnosis of malignancy, benign reactions can
also stain positively for these markers [29]. Whilst positive staining with glucose trans-
porter 1 (GLUT1) may have a higher specificity for malignant cell populations in pleural
biopsy specimens [1], cytological studies demonstrate lower specificity, with 9/50 patients
with benign reactive mesothelial proliferations demonstrating positive polyclonal GLUT-1
staining in one study [30] and 14/38 participants with benign effusions staining positive in
another [31].
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Detection of specific mesothelioma-associated genetic mutations can help confirm the
presence of malignant cells. Loss of BAP1 can be demonstrated on IHC staining and is
highly specific for malignancy, whilst fluorescent in situ hybridisation (FISH) can detect
deletion of the CDKN2A/P16 gene, commonly seen in MPM.
3.1.1. BAP1 Loss
BAP1 is a nuclear ubiquitin hydrolase, which functions as a tumour suppressor, and is
encoded by the BAP1 gene. It controls DNA repair, expression of genes related to cell cycle
and cell proliferation. It can also induce cell death. Cells with reduced or absent BAP1
are unable to repair damaged DNA and cannot execute apoptosis. BAP1-mutant cells are
therefore prone to malignant transformation [10].
Somatic mutation of the BAP1 gene in mesothelioma was first described in 2011, with
mutations occurring in approximately 70% of epithelioid mesotheliomas [10]. Germline
BAP1 mutation is less common, occurring in approximately 1–2% of MPM, usually in the
context of the autosomal dominant BAP1 cancer predisposition syndrome [29,32]. Germline
BAP1 loss is associated with earlier onset MPM tumours, as well as other BAP1-related
malignancies such as uveal melanoma.
BAP1 loss (defined as absence of nuclear staining when a positive internal control
is present on a slide) may occur by mutation, biallelic deletion or deletion/insertion [8]
and is most reliably detected by IHC [32]. Cells expressing at least one wild-type copy of
BAP1 retain IHC staining. Notably, even in tumours arising from germline BAP1 mutation,
non-tumour cells express a single wild-type copy and hence produce a positive IHC
response. To show loss of BAP1 immunoreactivity, both copies must be mutated, either by
a combination of germline and somatic mutation events, as in BAP1 cancer syndrome, or
by two somatic events in sporadic cancers [29].
Loss of BAP1 expression has been repeatedly validated in differentiating MPM from
benign mesothelial populations and is now in routine use in many pathology laboratories.
A recent meta-analysis identified 12 studies of 1824 patients (1016 with MPM), published
between 2015 and 2017. The overall pooled sensitivity of BAP1 loss for malignant mesothe-
lioma was 0.56 (95% CI: 0.50–0.62) and specificity 1.00 (95% CI: 0.95–1.00). The area under
curve (AUC) was 0.72, indicating moderate diagnostic accuracy. Notably, all studies were
of retrospective design, and only four included more than 100 participants. Heterogeneity
was evident, with potential explanations including different cut-off values for BAP1 loss,
inclusion of participants with pleural and peritoneal mesothelioma and variation in diag-
nostic accuracy across mesothelioma histological subtypes. For example, the sensitivity
ranged from 0.07 (95% CI: 0.00–0.72) in sarcomatoid MPM to 0.74 (95% CI: 0.66–0.80) in
epithelioid [33]. Offering additional explanation for this low diagnostic sensitivity, 30–40%
of mesotheliomas have been shown to carry a wild-type BAP1 and therefore stain positively
in a similar manner to benign lesions [10].
In a subgroup meta-analysis comparing the diagnostic performance of BAP1 loss in
histology and cytology specimens, near identical sensitivity and specificity was observed.
However, data from the 5 studies evaluating cytology specimens demonstrated reduced
diagnostic accuracy with an AUC of 0.69 [33]. Studies of BAP1 loss in cytology speci-
mens have, to date, been hindered by retrospective design, small sample size and the
use of cytology specimens in subgroup analyses. Well-designed research is required to
accurately determine the diagnostic potential of BAP1 loss in cytology specimens in order
to improve current diagnostic pathways and potentially avoid the need for additional
invasive procedures.
As a stand-alone test, BAP1 loss has moderate diagnostic sensitivity with excellent
specificity for MPM. BAP1 loss is therefore reliable as a “rule in” for mesothelioma, but
pleural malignancy cannot be excluded in its absence. Notably, BAP1 loss is uncommon in
sarcomatoid and desmoplastic mesothelioma and is demonstrated in other malignancies
including melanoma and renal cell carcinoma [34]. Superior diagnostic accuracy may be
achieved in combination with other adjunctive tests.
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3.1.2. p16 Fluorescence In Situ Hybridization (FISH)
Homozygous deletion of the 9p21 locus is one of the most common genetic alterations
in MPM. Its loss affects a cluster of genes, including p16 (also known as cyclin-dependent
kinase inhibitor (CDKN)-2A), CDKN2B and methylthioadenosine phosphorylase (MTAP).
p16/CDKN2A is a tumour suppressor gene that is present in all healthy cells. Its normal
function results in the cessation of the cell cycle; hence, inactivation results in uncontrolled
cell proliferation and tumour development.
Homozygous deletion of P16 can be detected using FISH in both cytological and
histological specimens [35]; however, the diagnostic sensitivity for MPM is relatively low at
0.53 (95% CI: 0.35–0.70), despite gene profiling studies demonstrating p16/CDKN2A loss
in up to 80% of MPM tumours. In part, the low sensitivity reflects variation in p16 deletion
across the different MPM subtypes (90–100% loss in sarcomatoid variant compared with a
70% loss in epithelioid and biphasic), although other alterations that affect the 9p21 locus
and cannot be detected by FISH also contribute [1,8,21,23,24,29].
An alternative approach, where histological specimens are available, is the application
of IHC staining to determine p16 protein expression in cells, which could represent a more
accessible ancillary test to laboratories where FISH cannot be performed [36]. However,
the sensitivity to discriminate MPM from reactive mesothelial hyperplasia using p16
IHC in combination with BAP1 loss was 10% lower than those of more traditional FISH
techniques in one study [35]. IHC techniques may be employed, in addition, to detect
MTAP loss, distinguishing malignant from benign proliferations with a specificity of 100%
and a sensitivity of 43% (increased to 79.5% when used in combination with BAP1 IHC) in
cell block specimens from pleural effusions [37,38]. IHC for MTAP can also discriminate
sarcomatoid MPM from fibrous pleuritis. A more recent multicentre evaluation of MTAP
loss by IHC demonstrated a 78% sensitivity and a 96% specificity for CDKN2A homozygous
deletion, suggesting it to be a reliable surrogate for CDKN2A FISH [39]; however, the use
of MTAP is not yet recommended by international guidelines [1,8,15].
Overall, when used in isolation, both FISH and IHC techniques for p16 deletion are
limited by low sensitivity. Consequently, whilst p16 deletion can confirm a suspected
diagnosis of malignancy, failure to detect its loss does not exclude a diagnosis of MPM.
However, combining testing for p16 loss with IHC for BAP1 loss has been shown to increase
diagnostic sensitivity (combined sensitivity 0.76 (95% CI: 0.62–0.88)) [40]. Therefore, if BAP1
is intact or a sarcomatoid mesothelioma is suspected, additional testing with p16 FISH
may strengthen diagnostic certainty [21] and help to discriminate benign from malignant
mesothelial cell populations (Figure 1).
Figure 1. A suggested diagnostic approach where distinction of malignant from benign mesothelial
proliferation is unclear on initial fluid cytology. BAP1 loss and p16 deletion support the diagnosis
of MPM. MPM, malignant pleural mesothelioma; ICC, immunocytochemistry; FISH, fluorescence
in-situ hybridization; BAP1, BRCA 1-associated protein.
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3.2. Distinguishing Mesothelioma from Carcinoma
Distinguishing mesothelioma from other causes of malignant pleural effusion is criti-
cal in guiding therapeutic strategies and prognosis. Malignancies commonly metastasising
to the pleura include lung cancers, breast and gastrointestinal carcinomas. Distinction
between epithelioid MPM and carcinomas may be made on morphology and simple
histochemical staining alone. As no one marker exhibits a 100% specificity, guidelines rec-
ommend a combination of at least two positive mesothelial markers (calretinin, cytokeratin
5/6, Wilms tumour 1 and D2-40) and at least two negative adenocarcinoma IHC markers
(thyroid transcription factor 1 (TTF1), carcinoembryonic antigen (CEA) and Ber-EP4) (see
Table 1) [1]. Positive markers of other tumour types should be used for differential diag-
noses of metastatic carcinomas from other sources, such as hormone receptors in breast
and ovarian cancer and PAX8 in renal cell carcinoma [1,15,24].
BAP1 loss may play a role in differentiating mesothelioma from carcinoma, with loss
in 46/53 (87%) pleural and peritoneal mesotheliomas compared with 4/204 (2%) (p: <0.001)
carcinomas in one study [41]. Further evaluation of the role of BAP1 loss in this context is
required, however, before universal adoption is recommended.
3.3. Distinguishing Mesothelioma from Other Malignant Cell Neoplasms
Malignant pleural effusion may be the first presentation of an unknown primary
cancer. In this setting, appropriate immunocytochemical panels often enable a precise
diagnosis, starting with CK7 and CK20 staining [42]. Other differential diagnoses of
MPM depend on histologic category, with epithelioid MPM requiring distinction from
carcinomas, sarcomatoid MPM from sarcomas and other spindle cell neoplasms, mixed
MPM from other mixed or biphasic tumours such as synovial sarcoma and desmoplastic
MPM from fibrous pleuritis. Immunostain selection in this setting would depend on basic
morphology [24].
Affirmative markers used in the evaluation of epithelioid MPM are of limited utility
in sarcomatoid tumours. More usefully, cytokeratin markers, such as CAM5.2, are im-
portant in differentiating sarcomatoid MPM (positive staining) from sarcoma, which is
usually keratin-negative [43]. D2-40 (podoplanin) can be used to differentiate sarcomatoid
MPM from pulmonary sarcomatoid carcinoma (which also stains positively for TTF1,
napsin and p40/p63). Synovial sarcoma can be confirmed by molecular testing for the X;
18 translocation [24].
Table 1. Immunohistochemical markers for differentiating tumour types in malignant pleural effusion
[12,24]. Adapted from Bibby et al. [44].
Mesothelial Markers Adenocarcinoma Markers Other Markers
Calretinin TTF1 (lung and thyroid) Squamous cell lung cancer:p40, p63 and claudin 4





Gastrointestinal: CD20 and CDX-2
Gynaecological: PAX-8 and WT1
Prostate: PSA and PSMA
Breast: mammaglobin, GCDFP-15,
ER, PR and GATA3
Immunocytochemical markers are summarised in Table 1.
4. Diagnostic Biomarkers
Biomarkers present an attractive solution to diagnostic challenges posed by MPM,
and consequently, a large number of studies have evaluated potential targets in serum,
plasma, PF and exhaled breath. An ideal marker should be obtainable by minimally
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invasive means and be sufficiently sensitive to detect most cases of MPM, whilst also being
highly specific, to avoid false positive results and discriminate individuals with MPM from
other pathologies. Protein biomarkers of interest include mesothelin, osteopontin and
fibulin-3 [45].
4.1. Mesothelin
Identified in the early 1990s as a surface antigen on ovarian cancer cells, mesothelin
is a glycoprotein thought to play a role in cell adhesion and signalling. The mesothelin
gene, MSLN, encodes a precursor protein from which membrane-bound mesothelin and
a soluble protein megakaryocyte potentiating factor (MPF) are formed. These are com-
monly referred to as “soluble mesothelin-related peptides” (SMRPs). In normal tissue,
mesothelin is only found on mesothelial cells; hence, serum levels of SMRP are low. How-
ever, increased concentrations of SMRPs are found in serum samples of patients with
ovarian and pancreatic cancers, in addition to mesothelioma. In 2003, Robinson et al.
demonstrated that patients with MPM had significantly higher concentrations of serum
SMRP than asbestos-exposed healthy controls, non-asbestos-exposed healthy controls and
patients with non-mesothelioma malignant or inflammatory pleural disease. They reported
a sensitivity of 84% (95% CI: 73–93) and a specificity of 100% (95% CI: 91–100) for MPM.
SMRP concentrations were higher in patients with epithelioid tumours and in those with a
large tumour bulk (maximum tumour width: >3 cm) [11,46,47]. In contrast, SMRP was less
likely to be raised in people with sarcomatoid and biphasic disease; however, small study
numbers and non-disclosure of histologic subtype in some studies mean that accurate
sensitivity and specificity estimates are difficult to derive for these tumour subtypes [11].
Serum mesothelin has become the most widely studied diagnostic biomarker in
MPM, with a meta-analysis in 2014 identifying 28 relevant publications, involving 7550 pa-
tients [48]. Pooled sensitivity and specificity estimates were found to be 0.61 and 0.87,
respectively, lower than indicated in previous studies. This is mostly accounted for by
heterogeneity across the included studies, although publication bias may also play a role.
Heterogeneity arose from the use of various ELISA assays, different cut-off values and
differences in participant characteristics (i.e., mesothelioma subtypes and choice of control
groups). The negative likelihood ratio (NLR) value was 0.43, meaning if participants were
serum-SMRP-negative, the probability of having MPM was still moderate at 43%. The
authors reported that low sensitivity limited the added value of SMRPs but a positive
result may be helpful in confirming MPM, with a positive likelihood ratio of 5.71 [48].
PF mesothelin has been studied as an alternative biomarker, as mesothelin is shed
from mesothelioma tumour cells directly into pleural effusion fluid. In 2005, Pass et al.
identified that SMRP levels were significantly higher in PF samples from 45 patients with
MPM compared to 30 healthy controls [49]. In the first study to assess the clinical utility of
PF SMRP, Davies et al. demonstrated levels were 10.9 times greater in patients with MPM
compared to benign pleural disease and were highly reproducible [50]. They concluded
that the measurement of PF mesothelin contributed valuable additional information to
PF cytology alone, especially where initial cytology results were inconclusive. In a meta-
analysis by Cui et al., pooled estimates of sensitivity were higher for PF SMRP than serum
samples (0.79 compared to 0.61) with PF SMRP specificity remaining robust at 0.85 [48].
Although considered as the current “gold standard” biomarker for MPM in some
international guidelines [15], neither serum nor pleural fluid mesothelin is recommended
as diagnostic tests in isolation. With low sensitivity, a negative result adds little value and
is a frequent finding in non-epithelioid disease. In contrast, a positive result increases the
likelihood of mesothelioma; however, false positives are possible in benign inflammatory
conditions such as benign asbestos pleural effusion (BAPE) or in the presence of impaired
renal function [51]. Consequently, mesothelin testing should be considered as an adjunct
in patients with suspicious or inconclusive cytology, who are unsuitable for or decline
invasive diagnostic tests with a high pre-test probability of MPM [1,4,8]. Further research
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into the utility of biomarkers in MPM diagnosis and better understanding of markers of
non-epithelioid disease may help to elucidate the role of this test in the diagnostic pathway.
4.2. Other Diagnostic Biomarkers
Osteopontin, a protein mediator of cell matrix interaction, cell signalling and tumour
development, has been viewed as a promising biomarker for MPM, but results have been
inconsistent. In a meta-analysis of six studies, the overall diagnostic sensitivity and speci-
ficity were 0.65 (95% CI: 0.6–7.0) and 0.81 (95% CI: 0.78–0.85), respectively. Notably, the
majority of included studies evaluated serum and/or plasma osteopontin from frozen sam-
ples with uncertainty regarding the long-term stability of osteopontin in frozen specimens.
Degradation of osteopontin during the freezing and defrosting process may explain the
low detection rates of this protein in retrospective studies [52]. Similar to mesothelin, the
clinical utility of osteopontin is limited by low sensitivity, and further understanding of its
added diagnostic value in comparison to other biomarkers is required.
Fibulin 3, an extracellular matrix glycoprotein mediator of cell-to-cell and cell-to-
matrix communication, is detectable in blood and PF with a small number of studies
reporting varied outcomes on its potential as a biomarker for MPM. Initially promising,
with a 97% sensitivity and a 95% specificity to determine MPM from other causes of
pleural effusion in one study [53], subsequent analyses have suggested a sensitivity as
low as 22% [54]. A questionable diagnostic value was highlighted by one study, with
no difference in fibulin 3 levels in pleural effusion samples of patients with MPM and
controls. Whilst plasma levels were higher in patients with MPM compared to in controls
in a population in Sydney, this was not replicated in a cohort of patients studied in Vienna
and the diagnostic accuracy was low (receiver operating curve analyses overall accuracies
of 63.2% and 56.2% for correct diagnostic characterisation of MPM in the Sydney and
Vienna cohort, respectively). The authors did, however, observe that low pleural effusion
fibulin 3 levels were significantly associated with better survival [55]. A meta-analysis of
8 studies demonstrated a pooled diagnostic sensitivity of blood fibulin 3 of 0.87 (95% CI:
0.58–0.97) and a specificity of 0.89 (95% CI: 0.77–0.95) [56]. A subsequent meta-analysis of
7 studies demonstrated a lower overall sensitivity from pooled studies of blood and pleural
effusion samples of 0.62 (95% CI: 0.45–0.77) and a specificity of 0.82 (95% CI: 0.73–0.89) [57].
Ultimately the value of fibulin 3 in diagnosing MPM remains unclear, with prospective
validation studies ongoing [58].
5. Imaging Techniques
CT with contrast enhancement is the primary imaging modality used for diagnosis
and staging of pleural malignancy and can identify the primary tumour, intrathoracic
lymphadenopathy and extrathoracic spread [59]. Positive features of malignant pleural
disease include circumferential pleural thickening, nodular pleural thickening, parietal
pleural thickening of greater than 1 cm and mediastinal pleural involvement [60]. The
diagnostic accuracies of CT for detection of pleural malignancy are 68–97% with specifici-
ties of 78–89% [1]. CT scanning is widely available and has high clinical utility. However,
it has limited soft tissue differentiation, and early malignant disease with minor pleural
thickening can be missed. Additionally, subtle invasion of certain structures may be chal-
lenging to identify, which has implications for the accuracy of staging. Timing of contrast
and reporting of images by non-thoracic radiologists add further variability. Subsequently,
35–46% of patients with pleural malignancy will have a “benign” CT report in routine
practice [61].
Differentiating mesothelioma from metastatic pleural malignancy can also be challeng-
ing. Parenchymal lung tumours with mediastinal or hilar lymphadenopathy may indicate
metastatic pleural disease, whereas the presence of pleural plaques, involvement of the
interlobar fissure and absence of lung parenchymal masses favour MPM [1]. It may be
particularly difficult to differentiate MPM from pleural metastatic disease, if the tumour
presents as a localised pleural or subpleural nodule, a localised anterior mediastinal mass
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or involves the diaphragmatic pleura with liver invasion, especially in the absence of a
pleural effusion [43].
Alternative imaging modalities have been proposed for use in MPM. Positron emission
technology (PET)-CT combines high-resolution CT scanning with an injection of a metabolic
tracer which accumulates at areas of metabolic activity. Uptake is assessed at regions of
interest and reported as standard uptake values (SUV), with a threshold value of 2.0 reliably
differentiating between benign and malignant disease [4]. A meta-analysis of 11 PET-CT
studies reported a pooled sensitivity of 95% (95% CI: 92–97%) and a specificity of 82%
(95% CI: 76–88%) for differentiating malignant from benign disease [62]. False positive
results are common, however, particularly in the context of prior talc pleurodesis, active
pleural infection, or indolent inflammation such as tuberculous pleuritis. PET-CT cannot
distinguish MPM from metastatic pleural disease and, due to poor spatial resolution, has
low sensitivity (78%) for extrapleural invasion [61]. Whilst lacking specificity to diagnose
MPM routinely, PET-CT may provide functional information on pleural lesions, although
it does not appear to be helpful in guiding choice of site for biopsy [63]. It is currently
recommended only for staging patients in whom the presence of distant metastatic disease
would alter treatment approach [1,8,15].
Magnetic resonance imaging (MRI) offers higher soft tissue contrast than CT, result-
ing in an increased sensitivity for chest wall and diaphragm invasion, higher contrast
with adjacent effusion and higher inter-observer agreement [64]. The contrast enhanced
perfusion augments sensitivity in detection of pleural malignancy, even where pleural
thickening is minimal [64]. In addition to differentiating malignant from benign pleural
disease, diffusion-weighted MRI (DWI-MRI) has distinguished between epithelioid and
sarcomatoid MPM with a sensitivity of 60% and a specificity of 94% [1]. At present, the
added value of MRI in equivocal or atypical CT scans is unclear, with prospective evalua-
tion required, but, where available, MRI may be considered in difficult diagnostic cases to
better delineate invasive disease [1,8,15].
6. Future Directions
The search for novel diagnostic biomarkers is expanding and encompasses multiple
branches of medical science. Proteomic analysis has identified new panels of candidate
biomarkers [65] with prospective multicentre evaluation of a novel assay ongoing [58].
Gene-expression-based classification has outperformed BAP1 and p16 FISH [40]. Deeper
understanding of the genomic and epigenomic factors relevant to MPM may herald new
diagnostic techniques that better distinguish MPM from other tumours [66–68]. Circulating
plasma micro-RNA [69] and metabolomic profiling [70,71] of PF are other experimental
areas of interest.
Whilst these studies may yield new markers which negate the requirement for invasive
tissue sampling, all are limited currently to the research setting and are not yet available in
clinical practice.
As the range of therapeutic options for MPM expands, the importance of genetic and
molecular phenotyping of tumours to enable targeted treatment will increase. Currently, no
marker is able to provide this level of personalised tumour phenotyping, so tissue biopsies
are likely to remain the diagnostic gold standard for the foreseeable future.
To obtain tissue in patients fit to undergo invasive procedures, a “direct-to-LAT” ap-
proach (pathway stratification where selected patients proceed directly to local anaesthetic
thoracoscopy (LAT) to obtain pleural biopsies) may be employed in patients where the
pre-test probability of MPM is high and the anticipated yield from PF cytology is low [72].
However, a streamlined diagnostic approach is required for more frail patients and those
who choose not to undergo pleural biopsy. Research to determine the combined value of
the investigations discussed in this article is essential to formalise integrated non-invasive
pathways for the diagnosis of MPM.
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7. Conclusions
For patients in whom malignant pleural mesothelioma is suspected, tissue diagno-
sis remains the gold standard and is the only method that can confirm the presence of
invasive disease. However, for those unable or unwilling to undergo tissue sampling, the
low sensitivity of pleural effusion cytology can be augmented by incorporating ancillary
techniques such as immunocytochemical markers to increase reliability [8]. No adjunc-
tive test has a sensitivity and specificity profile to support use in isolation, but findings
such as BAP1 loss can provide additional support for a suspected diagnosis if the pre-test
probability is high. Where diagnoses remain challenging, even despite use of ancillary
techniques, expert radiological review of disease distribution on imaging and occupational
history of asbestos exposure are important considerations. Correlation of PF cytology
with relevant radiology and supplementary biomarkers can enable an MDT-consensus
clinico-radiological-cytological diagnosis to be made, where further invasive tests are not
possible or not appropriate [18]. Diagnostic challenges surrounding non-epithelioid MPM
are recognised, and there is a critical need for reliable and non-invasive investigative tools
in this population.
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